Full Coverage

Astellas, Medivation to develop, commercialize MDV3100 for treatment of prostate cancer

                   
ucla.edu
Nov 4, 2009
 
Story Timeline:  18 days

The companies will use a compound developed in UCLA laboratories By Stuart Wolpert November 04, 2009 Category: Health Sciences, Research Astellas Pharma Inc. of Japan and California's Medivation Inc. have announced a global... [read full story]                    

powered by
Add Comment
Latest article on this story:

Medivation Lags Expectations (Zacks.com)

 yahoo.com Nov 6, 2009
First article on this story:

Chemical compound is basis for prostate cancer drug

 universityofcalifornia.edu Nov 4, 2009
Selected publications with coverage of this story:
universityofcalifornia.edu ucla.edu yahoo.com
RELATED
Found 2 documents:
                   

Medivation Lags Expectations (Zacks.com)

yahoo.com
Nov 6, 2009
 

has reported a net loss of 42 cents per share in the third quarter of 2009, exceeding the Zacks Consensus Estimate of a net loss of 39 cents. Revenue for the quarter was $16.3 million, consisting of partial recognition of the...

powered by
                   

Chemical compound is basis for prostate cancer drug

universityofcalifornia.edu
Nov 4, 2009
 

Astellas Pharma Inc. of Japan and California's Medivation Inc. have announced a global agreement to develop and commercialize MDV3100, a chemical compound developed in UCLA science laboratories that is now Medivation's...

powered by